The JAK2(V617F) mutation may be present several years before the occurrence of overt myeloproliferative disorders.

Suppr

超能文献

作者信息

Bellanné-Chantelot C, Jego P, Lionne-Huyghe P, Tulliez M, Najman A

出版信息

Leukemia. 2008 Feb;22(2):450-1. doi: 10.1038/sj.leu.2404896. Epub 2007 Sep 13.

DOI:10.1038/sj.leu.2404896

PMID:17851561

Abstract

摘要

相似文献

The JAK2(V617F) mutation may be present several years before the occurrence of overt myeloproliferative disorders.

Leukemia. 2008 Feb;22(2):450-1. doi: 10.1038/sj.leu.2404896. Epub 2007 Sep 13.

Occurrence of the JAK2 V617F mutation in the Budd-Chiari syndrome.布加综合征中JAK2 V617F突变的发生情况。

Blood Coagul Fibrinolysis. 2008 Jul;19(5):459-62. doi: 10.1097/MBC.0b013e3283049662.

JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders.JAK2（V617F）作为一种获得性体细胞突变以及与家族性骨髓增殖性疾病疾病进展相关的继发性遗传事件。

Cancer. 2006 Nov 1;107(9):2206-11. doi: 10.1002/cncr.22240.

The JAK2(V617F) tyrosine kinase mutation in myeloproliferative disorders: Summary of published literature and a perspective.骨髓增殖性疾病中的 JAK2(V617F)酪氨酸激酶突变：文献综述及观点。

Curr Hematol Malig Rep. 2006 Jun;1(2):75-80. doi: 10.1007/s11899-006-0026-3.

Pathogenetic role of JAK2 V617F mutation in chronic myeloproliferative disorders.JAK2 V617F突变在慢性骨髓增殖性疾病中的致病作用。

J Chin Med Assoc. 2007 Mar;70(3):89-93. doi: 10.1016/S1726-4901(09)70337-5.

Prevalence of JAK2 V617F mutation in Indian patients with chronic myeloproliferative disorders.印度慢性骨髓增殖性疾病患者 JAK2 V617F 突变的流行率。

Indian J Med Res. 2010 Oct;132:423-7.

JAK2 V617F: implications for thrombosis in myeloproliferative diseases.JAK2 V617F：对骨髓增殖性疾病中血栓形成的影响

Curr Opin Hematol. 2007 Sep;14(5):450-4. doi: 10.1097/MOH.0b013e3282861d1b.

Constitutive JunB expression, associated with the JAK2 V617F mutation, stimulates proliferation of the erythroid lineage.与JAK2 V617F突变相关的组成型JunB表达刺激红系谱系的增殖。

Leukemia. 2009 Jan;23(1):144-52. doi: 10.1038/leu.2008.275. Epub 2008 Oct 9.

Detection of the JAK2 V617F missense mutation by high resolution melting analysis and its validation.通过高分辨率熔解分析检测JAK2 V617F错义突变及其验证

Clin Chim Acta. 2009 Oct;408(1-2):39-44. doi: 10.1016/j.cca.2009.07.002. Epub 2009 Jul 10.

No evidence for amplification of V617F JAK2 in myeloproliferative disorders.在骨髓增殖性疾病中无V617F JAK2扩增的证据。

Leukemia. 2007 Dec;21(12):2561-3. doi: 10.1038/sj.leu.2404845. Epub 2007 Jul 5.

引用本文的文献

Germline duplication of ATG2B and GSKIP predisposes to familial myeloid malignancies.胚系 ATG2B 和 GSKIP 基因重复导致家族性髓系恶性肿瘤。

Nat Genet. 2015 Oct;47(10):1131-40. doi: 10.1038/ng.3380. Epub 2015 Aug 17.

Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.骨髓增殖性肿瘤中的新突变及其功能和临床相关性：JAK2、MPL、TET2、ASXL1、CBL、IDH 和 IKZF1。

Leukemia. 2010 Jun;24(6):1128-38. doi: 10.1038/leu.2010.69. Epub 2010 Apr 29.

Low burden of a JAK2-V617F mutated clone in monoclonal haematopoiesis in a Japanese woman with Budd-Chiari syndrome.一名患有布加综合征的日本女性单克隆造血中JAK2-V617F突变克隆的低负荷

Int J Hematol. 2009 May;89(4):517-522. doi: 10.1007/s12185-009-0280-y. Epub 2009 Mar 24.

Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders.髓系增殖性疾病中作为癌基因和药物靶点的突变型ABL1和JAK2的比较。

Leukemia. 2008 Jul;22(7):1320-34. doi: 10.1038/leu.2008.133. Epub 2008 Jun 5.

本文引用的文献

JAK2 (V617F) mutation in healthy individuals.

Br J Haematol. 2007 Feb;136(4):678-9. doi: 10.1111/j.1365-2141.2006.06483.x.

The myeloproliferative disorders.骨髓增殖性疾病

N Engl J Med. 2006 Dec 7;355(23):2452-66. doi: 10.1056/NEJMra063728.

JAK2(V617F): Prevalence in a large Chinese hospital population.JAK2（V617F）：在中国一家大型医院人群中的患病率。

Blood. 2007 Jan 1;109(1):339-42. doi: 10.1182/blood-2006-03-009472. Epub 2006 Aug 31.

The JAK2V617F mutation is detectable at very low level in peripheral blood of healthy donors.在健康供者的外周血中可检测到极低水平的JAK2V617F突变。

Leukemia. 2006 Sep;20(9):1622. doi: 10.1038/sj.leu.2404292. Epub 2006 Jun 15.

Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders.72个骨髓增殖性疾病家族中Val617Phe JAK2突变的遗传学及临床意义

Blood. 2006 Jul 1;108(1):346-52. doi: 10.1182/blood-2005-12-4852. Epub 2006 Mar 14.

Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders.两种用于评估慢性骨髓增殖性疾病中JAK2 V617F突变的临床实用检测方法的验证

Leukemia. 2006 Jan;20(1):168-71. doi: 10.1038/sj.leu.2404007.

The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease.正常个体白细胞中典型和非典型BCR-ABL融合基因的存在：生物学意义及对微小残留病评估的影响

Blood. 1998 Nov 1;92(9):3362-7.

Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals.在一些健康个体的血细胞中检测到极低水平的主要bcr-abl基因表达。

Blood. 1995 Oct 15;86(8):3118-22.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验